Antonio Pérez Martínez
Head of the Paediatric Haematology-Oncology Department at the Hospital Universitario La Paz.
This is a very important issue for several reasons:
There is evidence in clinical trials and scientific recommendations that recommend blinatumomab for example in post-treatment relapses, to induce remission and then go on to a transplant and even as a bridge to CAR-T therapy.
This study associated with chemotherapy improves the results of chemotherapy (iNFANT protocol).
Hopefully, these studies will improve the accessibility of these immunotherapies, which in our country is vetoed by the pharmacy services.
We have just published our experience with acute lymphoblastic leukaemia (ALL) in young children (34 patients), and these are results that need to be improved with strategies combined with chemotherapy, such as immunotherapy.
As these are drugs with a high economic impact, access is being blocked in many hospitals, and when we ask for them, the pharmacy services mostly deny access.
Evidence such as this will help us to optimise it.